Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.

You may also be interested in...



NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.

UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel